NDC product
Verapamil Hydrochloride
NDC 25021-312 · Sagent Pharmaceuticals
Key facts
| Product NDC | 25021-312 |
|---|---|
| Proprietary name | Verapamil Hydrochloride |
| Nonproprietary name | Verapamil Hydrochloride |
| Substances | VERAPAMIL HYDROCHLORIDE |
| Dosage form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Sagent Pharmaceuticals |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA214361 |
| Pharmacologic classes | Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA] |
| Marketing start | Mar 15, 2021 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: